XML 26 R12.htm IDEA: XBRL DOCUMENT v3.24.1.u1

Accounts payable and accrued expenses

3 Months Ended

Mar. 31, 2024

Payables and Accruals [Abstract]

Accounts payable and accrued expenses

5.        Accounts payable and accrued expenses

Accounts payable and accrued expenses at March 31, 2024 and December 31, 2023 consist of the following:

​

​	​	​	​	​	​	​	​
​	​	March 31,		​	December 31,		​
​		2024			2023		​
Employee compensation, benefits, and related accruals	​	$	35,060	​	$	62,643	​
Income tax payable	​	​	1,833	​	​	—	​
Consulting and contracted research	​		22,745	​		27,500	​
Professional fees	​		2,380	​		2,246	​
Sales allowance	​		67,075	​		77,176	​
Sales rebates	​		132,047	​		131,334	​
Royalties	​	​	28,952	​	​	74,111	​
Accounts payable	​		27,459	​		6,045	​
Other	​		13,373	​		10,928	​
Total	​	$	330,924	​	$	391,983	​

​

As of March 31, 2024 and December 31, 2023, there were $1.7 million and $9.0 million, respectively, of accrued restructuring costs included above within employee compensation, benefits, and related accruals from a reduction in workforce in the year ended December 31, 2023 in connection with the Company’s strategic pipeline prioritization and discontinuation of its preclinical and early research programs in its gene therapy platform.

X

- Definition

The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.

+ References

No definition available.

+ Details

Name:	us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_PayablesAndAccrualsAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration